News

Article

Fathers with Type 1 Diabetes May Be More Likely to Pass on Disease than Mothers

An analysis of more than 11,000 people with T1D found people were more likely to report an affected father than an affected mother.

Lowri Allen, PhD | Credit: GW4-CAT PhD Programme

Lowri Allen, PhD
Credit: GW4-CAT PhD Programme

Fathers carry nearly double the risk of passing type 1 diabetes down to their children than mothers with the disease, according to a new analysis.

An early data release from this year’s Annual Meeting of the European Association for the Study of Diabetes (EASD), the meta-analysis, which included data from more than 11,000 people with type 1 diabetes, indicates people with type 1 diabetes were 1.8 times more likely to have a father with type 1 diabetes as they were to have a mother with the autoimmune condition.1

“Taken together, our findings suggest the relative protection associated with having a mother versus father with type 1 diabetes is a long-term effect that extends into adult life,” said principal investigator Lowri Allen, PhD, of the Diabetes Research Group at Cardiff University.2

Type 1 diabetes represents an area of significant unmet need for public health systems. However, although progress has not addressed the unmet need within type 1 diabetes management, the therapeutic pipeline has begun to produce several promising agents, including the first FDA-approved therapy for delaying the progression of type 1 diabetes in teplizumab (Tzield). Beyond teplizumab, which boasts a specific indication for delaying the onset of stage 3 type 1 diabetes, other agents, such as the stem cell-derived VX-880, have given the community hope their race for a cure may soon have a finish line in sight.3,4

Still even with this therapeutic progress, the causes of type 1 diabetes remain unknown and risk factors represent a knowledge gap with significant clinical implications given reports of growing rates of type 1 diabetes in recent years.5

With this in mind, Allen and a team of colleagues from institutions in the UK, Sweden, and United States designed the current research endeavor as a meta-analysis of data from the BOX, Better Diabetes Diagnosis, TrialNet Pathway to Prevention Study, Type 1 Diabetes Genetic Consortium, StartRight cohorts. Leveraging these cohorts, investigators identified a cohort of 11,475 individuals aged 0 to 88 years with type 1 diabetes for inclusion.1

The primary outcome of interest for the study was the proportion of patients with affected fathers versus mothers. Of note, investigators planned secondary analyses to determine if this comparison was altered by age at diagnosis or timing of parental diagnosis relative to offspring growth. Additionally, investigators expressed an interest in exploring differences in GRS2 type 1 diabetes genetic risk score between individuals with mothers and fathers with type 1 diabetes.1

Investigators found have a father with type 1 diabetes was nearly twice as common as having a mother with type 1 diabetes among those included in the study (Odds Ratio [OR], 1.79; 95% Confidence Interval [CI], 1.59 to 2.03; P <.0001). Analysis according to time at diagnosis suggested the likelihood of having an affected father was greater than having an affected mother regardless of whether or not a patient was diagnosed with type 1 diabetes prior to turning 18 years of age (OR, 1.64;95% CI, 1.14 to 2.37; P <.0001) or diagnosed at 18 years or older (OR, 1.80; 95% CI., 1.58 to 2.05; P <.0001).1

Further analysis indicated the increased likelihood of having a father with type 1 diabetes was only significant if the diagnosis occurred prior to offspring birth (OR, 1.92; 95% CI, 1.30 to 2.83; P = .001), but this association failed to achieve statistical significance for those diagnosed after offspring birth (OR, 1.29; 95% CI, 0.94 to 1.65; P = .12). Results also indicated age at diagnosis and type 1 diabetes-free survival curves were comparable amongst offspring of affected fathers and mothers (P=.31 and P=.94, respectively). Investigators pointed out there were no significant differences observed in GRS2 between individuals with affected fathers versus mothers (P = .31).1

“This study, the largest to investigate the risk of type 1 diabetes in individuals with affected mothers and fathers, has enriched our understanding of the differences in parental risk, relative maternal protection from type 1 diabetes and underlying mechanisms,” said Richard Oram, MD, PhD, of the Department of Clinical and Biomedical Sciences, University of Exeter Medical School.2

References:

  1. Allen LA, Taylor PN, Carson A, et al. Maternal type 1 diabetes confers long-term relative protection against type 1 diabetes in the offspring: results from five cohort studies. Presented at: 2024 Annual Meeting of the European Association for the Study of Diabetes (EASD). September 9 - 13, 2024. Madrid, Spain.
  2. European Association for the Study of Diabetes (EASD). Children are less likely to have type 1 diabetes if their mother has the condition than if their father is affected. EurekAlert! July 26, 2024. Accessed July 30, 2024. https://www.eurekalert.org/news-releases/1052563.
  3. Campbell P. Teplizumab receives FDA approval for delaying type 1 diabetes. HCP Live. November 17, 2022. Accessed July 30, 2024. https://www.hcplive.com/view/teplizumab-receives-fda-approval-for-delaying-type-1-diabetes.
  4. American Diabetes Association. Expanded forward trial demonstrates continued potential for stem cell-derived islet cell therapy to eliminate need for insulin for people with T1D. American Diabetes Association Newsroom. June 21, 2024. Accessed July 30, 2024. https://diabetes.org/newsroom/press-releases/expanded-forward-trial-demonstrates-continued-potential-stem-cell-derived.
  5. Gong B, Yang W, Xing Y, Lai Y, Shan Z. Global, regional, and national burden of type 1 diabetes in adolescents and young adults. Pediatr Res. Published online March 5, 2024. doi:10.1038/s41390-024-03107-5

Related Videos
Ben Samelson-Jones,Ben Samelson-Jones, MD, PhD: Validating Long-Term Safety of Hemophilia AAV Gene Therapy MD, PhD: Validating Long-Term Safety of Hemophilia AAV Gene Therapy
Françoise Bernaudin, MD: A Decade of Follow-up Reveals allo-SCT Superiority Over SOC for Sickle Cell Anemia
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Marlyn Mayo, MD: Improving Pruritus Management in PBC Care
Achieving Quick Responses in Sickle Cell Anemia With Early, Appropriate Hydroxyurea Dosing, with Abena Appiah-Kubi, MD, MPH
Steven W. Pipe, MD: Fitusiran With Anti-Thrombin Modulation Yields Effective Bleed Control, Reduces Infusions
Highlighting the Danger of SCI Progression during iTTP Remission, with Shruti Chaturvedi, MBSS, MS
© 2024 MJH Life Sciences

All rights reserved.